Diamide compounds having muscarinic receptor antagonist and β
This invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and β 2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.
1. A process for preparing a compound of the formula:
or a pharmaceutically acceptable salt thereof, the process comprising deprotecting a compound of the formula:
or a salt thereof; wherein R x and R y are independently selected from C 1-4 alkyl, phenyl, and —C 1-4 alkyl-(phenyl); and R z is selected from C 1-4 alkyl, phenyl, —C 1-4 alkyl-(phenyl) and —O—(C 1-4 alkyl).
2. The process of claim 1 , wherein R x and R y are methyl; and R z is tert-butyl.
3. The process of claim 1 , wherein the compound is deprotected by contacting the compound with a source of fluoride ion.
4. The process of claim 1 , wherein the compound is deprotected by contacting the compound with triethylamine trihydrofluoride.
5. The process of claim 1 , wherein R x and R y are methyl; and R z is tert-butyl; and the compound is deprotected by contacting the compound with triethylamine trihydrofluoride.